When should Surgery be used for Recurrent Ovarian Carcinoma?

被引：27

作者：

Bommert, M. ^{[1
]}

Harter, P. ^{[1
]}

Heitz, F. ^{[1
]}

du Bois, A. ^{[1
]}

机构：

[1] Kliniken Essen Mitte, Dept Gynecol & Gynecol Oncol, Henricistr 92, D-45136 Essen, Germany

来源：

CLINICAL ONCOLOGY | 2018年 / 30卷 / 08期

关键词：

Ovarian cancer; recurrence; secondary cytoreductive surgery; SECONDARY CYTOREDUCTIVE SURGERY; PHASE-III TRIAL; PEGYLATED LIPOSOMAL DOXORUBICIN; EPITHELIAL OVARIAN; AGO SCORE; EXPLORATORY ANALYSIS; MAINTENANCE THERAPY; CANCER; CHEMOTHERAPY; PERITONEAL;

D O I：

10.1016/j.clon.2018.04.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cytoreductive surgery is an important column in the treatment of primary ovarian cancer. Surgical outcome is one of the most important prognostic factors and one of the few prognostic variables that can be influenced by therapists. Retrospective studies suggested that only complete cytoreduction was associated with a benefit. Therefore, definition of predictors of complete resection is of the utmost importance to avoid surgical burden in patients with both limited benefit of the procedure and limited overall life expectancy. Two prospective multicentre randomised surgical trials in platinum-sensitive recurrent ovarian cancer (DESKTOP III [NCT #01166737] and GOG 213 [NSC #704865]) comparing secondary cytoreductive surgery followed by platinum-based chemotherapy versus chemotherapy alone have been conducted. The results of the DESKTOP III were recently presented at the American Society of Clinical Oncology meeting in Chicago. It showed a benefit of secondary cytoreductive surgery exclusively in patients with complete resection with a progression-free survival of 5.6 months (P < 0.001). This overview aims to support this task and concentrates on the currently available data regarding surgery in recurrent ovarian cancer. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

引用

页码：493 / 497

页数：5

共 36 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2] Surgical cytoreduction for recurrent epithelial ovarian cancer [J].

Al Rawahi, Thuria ;

Lopes, Alberto D. ;

Bristow, Robert E. ;

Bryant, Andrew ;

Elattar, Ahmed ;

Chattopadhyay, Supratik ;

Galaal, Khadra .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02)

[3] Advanced epithelial ovarian cancer:: 1998 consensus statements [J].

Berek, JS ;

Bertelsen, K ;

du Bois, A ;

Brady, MF ;

Carmichael, J ;

Eisenhauer, EA ;

Gore, M ;

Grenman, S ;

Hamilton, TC ;

Hansen, SW ;

Harper, PG ;

Horvath, G ;

Kaye, SB ;

Lück, HJ ;

Lund, B ;

McGuire, WP ;

Neijt, JP ;

Ozols, RF ;

Parmar, MKB ;

Piccart-Gebhart, MJ ;

van Rijswijk, R ;

Rosenberg, P ;

Rustin, GJS ;

Sessa, C ;

Thigpen, JT ;

Tropé, C ;

Tuxen, MK ;

Vergote, I ;

Vermorken, JB ;

Willemse, PHB .

ANNALS OF ONCOLOGY, 1999, 10 :87-92

[4] Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis [J].

Bristow, Robert E. ;

Puri, Isha ;

Chi, Dennis S. .

GYNECOLOGIC ONCOLOGY, 2009, 112 (01) :265-274

[5] The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas [J].

Chi, Dennis S. ;

Zivanovic, Oliver ;

Levinson, Kimberly L. ;

Kolev, Valentin ;

Huh, Jae ;

Dottino, Joseph ;

Gardner, Ginger J. ;

Leitao, Mario M., Jr. ;

Levine, Douglas A. ;

Sonoda, Yukio ;

Abu-Rustum, Nadeem R. ;

Brown, Carol L. ;

Barakat, Richard R. .

GYNECOLOGIC ONCOLOGY, 2010, 119 (01) :38-42

[6]

Coleman RL, 2015, ANN M SOC GYN ONC

[7] Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20 [J].

Du Bois, Andreas ;

Vergote, Ignace ;

Ferron, Gwenael ;

Reuss, Alexander ;

Meier, Werner ;

Greggi, Stefano ;

Jensen, Pernille Tina ;

Selle, Frededric ;

Guyon, Frederic ;

Pomel, Christophe ;

Lecuru, Fabrice ;

Zang, Rongyu ;

Avall-Lundqvist, Elisabeth ;

Kim, Jae Weon ;

Ponce, Jordi ;

Raspagliesi, Francesco ;

Ghaem-Maghami, Sadaf ;

Reinthaller, Alexander ;

Harter, Philipp ;

Sehouli, Jalid .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[8] Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) [J].

du Bois, Andreas ;

Reuss, Alexander ;

Pujade-Lauraine, Eric ;

Harter, Philipp ;

Ray-Coquard, Isabelle ;

Pfisterer, Jacobus .

CANCER, 2009, 115 (06) :1234-1244

[9]

Feldheiser A, 2015, ANTICANCER RES, V35, P1591

[10] Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer [J].

Ferrandina, Gabriella ;

Ludovisi, Manuela ;

Lorusso, Domenica ;

Pignata, Sandro ;

Breda, Enrico ;

Savarese, Antonella ;

Del Medico, Pietro ;

Scaltriti, Laura ;

Katsaros, Dionyssios ;

Priolo, Domenico ;

Scambia, Giovanni .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) :890-896

← 1 2 3 4 →